Abstract

Chimeric Antigen Receptor (CAR) T-cell therapy has demonstrated high rates of response in recurrent B-cell Acute Lymphoblastic Leukemia in children and young adults. Despite this success, a fraction of patients’ experience relapse after treatment. Relapse is often preceded by recovery of healthy B cells, which suggests loss or dysfunction of CAR T-cells in bone marrow. This site is harder to access, and thus is not monitored as frequently as peripheral blood. Understanding the interplay between B cells, leukemic cells, and CAR T-cells in bone marrow is paramount in ascertaining the causes of lack of response. In this paper, we put forward a mathematical model representing the interaction between constantly renewing B cells, CAR T-cells, and leukemic cells in the bone marrow. Our model accounts for the maturation dynamics of B cells and incorporates effector and memory CAR T-cells. The model provides a plausible description of the dynamics of the various cellular compartments in bone marrow after CAR T infusion. After exploration of the parameter space, we found that the dynamics of CAR T product and disease were independent of the dose injected, initial B-cell load, and leukemia burden. We also show theoretically the importance of CAR T product attributes in determining therapy outcome, and have studied a variety of possible response scenarios, including second dosage schemes. We conclude by setting out ideas for the refinement of the model.

Highlights

  • Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy technique consisting of the genetic modification of T-cells to allow them to recognize specific tumor antigens

  • Most clinical data obtained in Chimeric Antigen Receptor (CAR) T clinical trials are based on peripheral blood samples

  • Typical curves for CAR T dynamics can be found in refs. [22,23,24]

Read more

Summary

Introduction

Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy technique consisting of the genetic modification of T-cells to allow them to recognize specific tumor antigens. The product is re-infused into the patient for therapeutic purposes [1]. This is regarded as one of the most promising therapeutic advances in the fight against cancer, and is integrated into standard care for some hematological malignancies [2,3]. This marker is widely expressed in B cells but is absent from other cell types [4], making it an ideal target for immunotherapy. High response rates have been reported in B-cell Acute Lymphoblastic Leukemias and in Diffuse Large

Objectives
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call